Inventor · disambiguated record
Minh Diem Vu
Also filed as: VU MINH DIEM
7 granted patents·12 pending applications·55 citations·filing 2014–2022
84Inventor score
Top patents by PatentIndex Score
19 records- 0194US10683369B2Monoclonal antibodies against BCMAENGMAB SARL·Filed 2016·Granted Jun 16, 2020·14 cites·21 claims
- 0292US9963513B2Method for the selection of antibodies against BCMAENGMAB AG·Filed 2014·Granted May 8, 2018·19 cites·5 claims
- 0387US10253104B2Bispecific antibodies against CD3ϵ and BCMAENGMAB AG·Filed 2015·Granted Apr 9, 2019·10 cites·16 claims
- 0484US10077315B2Bispecific antibodies against CD3 and BCMAENGMAB AG·Filed 2014·Granted Sep 18, 2018·6 cites·5 claims
- 0582US11124577B2Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myelomaENGMAB SARL·Filed 2017·Granted Sep 21, 2021·5 cites·8 claims
- 0680US10851171B2Method for the selection of antibodies against BCMAENGMAB SARL·Filed 2018·Granted Dec 1, 2020·1 cites·4 claims
- 0773US2023322957A1Monoclonal antibodies against bcmaENGMAB SARL·Filed 2022·Application pending·0 cites
- 0868US2021070873A1Method for the selection of antibodies against bcmaENGMAB SARL·Filed 2020·Application pending·0 cites
- 0964US2020385471A1Bispecific antibodies against cd3epsilon and bcma for use in treatment of diseasesENGMAB SARL·Filed 2020·Application pending·0 cites
- 1062US2020283545A1Monoclonal antibodies against bcmaENGMAB SARL·Filed 2020·Application pending·0 cites
- 1160US2022017631A1Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myelomaENGMAB SARL·Filed 2021·Application pending·0 cites
- 1260US2022002427A1Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myelomaENGMAB SARL·Filed 2021·Application pending·0 cites
- 1356US2020255521A1Bispecific antibodies against cd3epsilon and ror1ENGMAB SARL·Filed 2020·Application pending·0 cites
- 1450US2016297881A1BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1ENGMAB AG·Filed 2014·Application pending·0 cites
- 1549US2023057602A1Methods of treatment with antibodies against bcma and cd3BRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 1646US11952421B2Bispecific antibodies against CD3EPSILON and ROR1BRISTOL MYERS SQUIBB CO·Filed 2015·Granted Apr 9, 2024·0 cites·6 claims
- 1742US2017327580A1Bispecific antibodies against cd3 epsilon and bcma for use in treatment of diseasesENGMAB AG·Filed 2015·Application pending·0 cites
- 1834US2017327579A1Bispecific antibodies against cd3epsilon and bcmaENGMAB AG·Filed 2015·Application pending·0 cites
- 1933US2017306044A1Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancerENGMAB AG·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Minh Diem Vu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →